Last Updated : May 19, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort ascending | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Zenhale | Mometasone/formoterol | Asthma | List with clinical criteria and/or conditions | Complete | ||
| Votrient | Pazopanib Hydrochloride | Soft Tissue Sarcoma | Do not reimburse | Complete | ||
| Onglyza | Saxagliptin | Diabetes mellitus, type 2 | Withdrawn | |||
| Lodalis | Colesevelam hydrochloride | Hypercholesterolemia | Do not list at the submitted price | Complete | ||
| Apprilon | Doxycycline monohydrate | Rosacea | Do not list | Complete | ||
| Toviaz | Fesoterodine fumarate | Overactive bladder | List in a similar manner | Complete | ||
| Lucentis | Ranibizumab injection | Macular edema, secondary to retinal vein occlusion | List with clinical criteria and/or conditions | Complete | ||
| Treanda | Bendamustine hydrochloride | Chronic Lymphocytic Leukemia (relapsed/refractory) | Do not reimburse | Complete | ||
| Treanda | Bendamustine hydrochloride | Chronic Lymphocytic Leukemia (first-line) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Treanda | Bendamustine hydrochloride | Non-Hodgkin Lymphoma and Mantle Cell Lymphoma | Reimburse | Complete |
Last Updated : May 19, 2024